MedTrace Logo

Fimasartan (BR-A-657) Multiple Oral Dose in Healthy Subjects

NCT01289899 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2011-02-04

No results posted yet for this study

Summary

The objective of this study is to determine the safety and tolerability and to determine the Pharmacokinetic and Pharmacodynamic(PK/PD) of ascending multiple oral dose of BR-A-657 in healthy male subjects.

Conditions

  • Essential Hypertension

Interventions

DRUG

BR-A-657

120, 360mg or placebo 7days

Sponsors & Collaborators

  • Covance

    collaborator INDUSTRY

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • E Engmann, MB ChB · Covance Clinical Research Unit

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2004-02-29
Completion
2004-02-29

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01289899 on ClinicalTrials.gov